Isotechnika entered a strategic investment and collaboration with Paladin Labs under which Paladin will provide Isotechnika with $7.0 million of cash upfront and $4.4 million in R&D funding during the next 12 months. Under the proposed plan, Isotechnika will own 81% of a new company, Isotechnika Pharma Inc., and Paladin will own 19%. Isotechnika will focus its efforts on finding partnerships for the clinical development of voclosporin in the transplant indication, and expects to have the ...